|
GB9726916D0
(en)
*
|
1997-12-19 |
1998-02-18 |
Danbiosyst Uk |
Nasal formulation
|
|
WO1999057106A1
(en)
*
|
1998-05-04 |
1999-11-11 |
The University Of Connecticut |
Novel analgesic and immunomodulatory cannabinoids
|
|
US7589220B2
(en)
*
|
1998-06-09 |
2009-09-15 |
University Of Connecticut |
Inhibitors of the anandamide transporter
|
|
US7897598B2
(en)
*
|
1998-06-09 |
2011-03-01 |
Alexandros Makriyannis |
Inhibitors of the anandamide transporter
|
|
US7161016B1
(en)
|
1998-11-24 |
2007-01-09 |
University Of Connecticut |
Cannabimimetic lipid amides as useful medications
|
|
US7276613B1
(en)
|
1998-11-24 |
2007-10-02 |
University Of Connecticut |
Retro-anandamides, high affinity and stability cannabinoid receptor ligands
|
|
US6566560B2
(en)
|
1999-03-22 |
2003-05-20 |
Immugen Pharmaceuticals, Inc. |
Resorcinolic compounds
|
|
HUP0203437A3
(en)
|
1999-03-22 |
2003-07-28 |
Immugen Pharmaceuticals Inc So |
Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
|
|
US8084467B2
(en)
*
|
1999-10-18 |
2011-12-27 |
University Of Connecticut |
Pyrazole derivatives as cannabinoid receptor antagonists
|
|
US7741365B2
(en)
*
|
1999-10-18 |
2010-06-22 |
University Of Connecticut |
Peripheral cannabinoid receptor (CB2) selective ligands
|
|
US7119108B1
(en)
*
|
1999-10-18 |
2006-10-10 |
University Of Connecticut |
Pyrazole derivatives as cannabinoid receptor antagonists
|
|
US7393842B2
(en)
*
|
2001-08-31 |
2008-07-01 |
University Of Connecticut |
Pyrazole analogs acting on cannabinoid receptors
|
|
US6900236B1
(en)
|
1999-10-18 |
2005-05-31 |
University Of Connecticut |
Cannabimimetic indole derivatives
|
|
US6995187B1
(en)
|
1999-10-18 |
2006-02-07 |
University Of Connecticut |
Peripheral cannabinoid receptor (CB2) selective ligands
|
|
US6943266B1
(en)
*
|
1999-10-18 |
2005-09-13 |
University Of Connecticut |
Bicyclic cannabinoid agonists for the cannabinoid receptor
|
|
US6808902B1
(en)
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
|
WO2001058469A1
(en)
*
|
2000-02-08 |
2001-08-16 |
Wax Martin B |
Methods for treating glaucoma
|
|
US6531128B1
(en)
|
2000-02-08 |
2003-03-11 |
Pharmacia Corporation |
Methods for treating glaucoma
|
|
AU5969101A
(en)
|
2000-05-12 |
2001-11-26 |
Genzyme Corp |
Modulators of tnf-alpha signaling
|
|
EP1785417A3
(en)
*
|
2000-06-22 |
2007-08-01 |
Pharmos Corporation |
Novel non-psychotropic cannabinoids
|
|
CA2411585A1
(en)
*
|
2000-06-22 |
2001-12-27 |
Pharmos Corporation |
Novel non-psychotropic cannabinoids
|
|
US7235584B2
(en)
*
|
2000-06-22 |
2007-06-26 |
Pharmos Corporation |
Non-psychotropic cannabinoids
|
|
WO2002026728A2
(en)
*
|
2000-09-28 |
2002-04-04 |
Immugen Pharmaceuticals, Inc. |
Antiviral methods and compounds
|
|
AU2001296402A1
(en)
*
|
2000-09-28 |
2002-04-08 |
Immugen Pharmaceuticals, Inc. |
Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
|
|
JP2004532185A
(ja)
*
|
2001-01-26 |
2004-10-21 |
ユニバーシティ オブ コネチカット |
新規なカンナビミメティックリガンド
|
|
JP2005503998A
(ja)
|
2001-01-29 |
2005-02-10 |
ユニバーシティ オブ コネチカット |
受容体選択性のカンナビミメティックアミノアルキルインドール
|
|
MY143582A
(en)
|
2001-06-26 |
2011-05-31 |
Amgent Fremont Inc |
Antibodies to opgl
|
|
US7057076B2
(en)
*
|
2001-07-13 |
2006-06-06 |
University Of Connecticut |
Bicyclic and tricyclic cannabinoids
|
|
EP1448557A4
(en)
*
|
2001-10-26 |
2005-02-02 |
Univ Connecticut |
HETEROINDANE: A NEW CLASS OF HIGH-ACTIVITY CANNABIMIMETIC LIGANDS
|
|
AU2003214226A1
(en)
*
|
2002-03-18 |
2003-10-08 |
Immugen Pharmaceuticals, Inc. |
Topical formulations of resorcinols and cannibinoids and methods of use
|
|
US20050137251A1
(en)
*
|
2002-03-18 |
2005-06-23 |
Aaron Garzon |
Dexanabinol and dexanabinol analogs regulate inflammation related genes
|
|
IL148736A0
(en)
*
|
2002-03-18 |
2002-09-12 |
Pharmos Corp |
Dexanabinol and dexanabinol analogs which regulate inflammation related genes
|
|
CA2496097A1
(en)
|
2002-08-23 |
2004-03-04 |
University Of Connecticut |
Keto cannabinoids with therapeutic indications
|
|
US20050192341A1
(en)
*
|
2002-09-05 |
2005-09-01 |
Seth Kindler |
Non-psychotropic cannabinoids for prevention of cognitive impairment
|
|
JP4928079B2
(ja)
*
|
2002-11-21 |
2012-05-09 |
ジェンザイム・コーポレーション |
慢性組織移植片拒絶を阻害するためのジアミド誘導体の使用
|
|
EP1562571B1
(en)
*
|
2002-11-21 |
2011-08-17 |
Genzyme Corporation |
Combination of a diamide derivative and immunosuppressive agents for inhibiting transplant rejection
|
|
JP2006509038A
(ja)
*
|
2002-12-04 |
2006-03-16 |
ファーモス コーポレイション |
医薬組成物用の高エナンチオマー純度を有するデキサナビノール
|
|
NZ594077A
(en)
*
|
2005-09-29 |
2013-02-22 |
Albany Molecular Res Inc |
Process for production of delta-9-tetrahydrocannabinol
|
|
WO2009059277A1
(en)
*
|
2007-11-02 |
2009-05-07 |
University Of South Florida |
Synergistic modulation of microglial activation by nicotine and thc
|
|
GB0915877D0
(en)
|
2009-09-10 |
2009-10-14 |
E Therapeutics Plc |
Cancer cell apoptosis
|
|
GB201207305D0
(en)
|
2012-04-26 |
2012-06-13 |
E Therapeutics Plc |
Therapy
|
|
AU2015280412B2
(en)
|
2014-06-26 |
2018-07-26 |
Island Breeze Systems Ca, Llc |
MDI related products and methods of use
|
|
US9585867B2
(en)
|
2015-08-06 |
2017-03-07 |
Charles Everett Ankner |
Cannabinod formulation for the sedation of a human or animal
|
|
WO2017068349A1
(en)
*
|
2015-10-23 |
2017-04-27 |
E-Therapeutics Plc |
Cannabinoid for use in immunotherapy
|
|
US12029718B2
(en)
|
2021-11-09 |
2024-07-09 |
Cct Sciences, Llc |
Process for production of essentially pure delta-9-tetrahydrocannabinol
|